Introduction: Atrial fibrillation (AF) is the most common sustained arrhythmia in women and men on a global level. Sex-specific differences in the baseline clinical and demographic features, management strategies and prognosis in patients with AF have been studied extensively but have received less attention in the Middle East Hypothesis: To compare the clinical characteristics, therapeutic strategies and one-year incidence of major cardiovascular events between women and men with AF Methods: The Jordan AF Study enrolled consecutive patients with AF in 29 hospitals and cardiology clinics in Jordan from May 2019 through December 2020. Patients were followed up for one year. We used the study data to compare clinical features, use of pharmaceutical agents and outcome in women compared with men Results: Of 2020 AF patients enrolled, 1095 (54.2%) were women. Women were older than men (mean age±SD 69.4±11.1 vs. 66.0±14.7 years, p<0.001), and had higher prevalence of hypertension, diabetes, and obesity. Compared with men, women with nonvalvular AF had higher mean CH2DS2-VASc score(4.1±1.7 vs. 3.0±1.8, p<0.001) and HAS-BLED score (1.7±1.1 vs. 1.6±1.2, p=0.05). High-risk CHA2DS2-VASc score was present in 83.9% of women and 78.9% of men (p=0.07), and oral anticoagulant agents were prescribed for 84.7% of women and 81.7% of men (p=0.14).At one year, women and men did not differ significantly in rates of all-cause death (12.0% vs. 13.1%, p=0.51), stroke/systemic embolism (4.1% vs. 4.8%, p=0.44), major bleeding events (2.0% vs. 3.2%, p=0.13), and intracranial bleeding (0.3% vs. 0.8%, p=0.24). Multiple logistic regression analysis showed no sex differences in one-year all-cause death. Moreover, age > 70 years, hypertension, diabetes, heart failure, ischemic heart disease were associated with higher incidence of all-cause death Conclusions: Despite the fact that Middle Eastern women with AF had worse baseline clinical profile and risk scores, they did not differ from men in one-year outcome. Female sex was not a predictor of one-year mortality in this cohort.